Swedish Orphan Biovitrum AB (publ) (Sobi) today published its Annual Report for 2014, themed "We have a story to tell", on the company's website, www.sobi.com.
The report summarises 2014, which was a pivotal year for the company. It encompasses Sobi's vision to pioneer a world in which patients with rare diseases are diagnosed at birth and receive effective and sustainable therapy, enabling them to live full and healthy lives. Sobi aims to develop new medicinal products and therapies and, through close dialogue with relevant stakeholders such as authorities, healthcare providers and patient organisations, to build a sustainable model for ensuring that these products reach patients over a lifetime.
Sobi's Annual Report includes interviews with key external stakeholders, giving their perspective on the development of the pharmaceutical industry and how it is to live with a rare disease, respectively.
---
About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.
For more information please contact
Media relations Investor relations
Oskar Bosson Jörgen Winroth
Head of Communications VP, Head of Investor Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506
oskar.bosson@sobi.com jorgen.winroth@sobi.com
Sobi Annual Report 2014 ENG http://hugin.info/134557/R/1911335/681927.pdf
HUG#1911335
